[go: up one dir, main page]

WO1996017869A3 - Antagonistes d'interleukine-6 (il-6) - Google Patents

Antagonistes d'interleukine-6 (il-6) Download PDF

Info

Publication number
WO1996017869A3
WO1996017869A3 PCT/IT1995/000208 IT9500208W WO9617869A3 WO 1996017869 A3 WO1996017869 A3 WO 1996017869A3 IT 9500208 W IT9500208 W IT 9500208W WO 9617869 A3 WO9617869 A3 WO 9617869A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
shil
asn
abnormal
interleukin
Prior art date
Application number
PCT/IT1995/000208
Other languages
English (en)
Other versions
WO1996017869A2 (fr
Inventor
Gennaro Ciliberto
Carlo Toniatti
Original Assignee
Angeletti P Ist Richerche Bio
Gennaro Ciliberto
Carlo Toniatti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio, Gennaro Ciliberto, Carlo Toniatti filed Critical Angeletti P Ist Richerche Bio
Priority to AU41866/96A priority Critical patent/AU4186696A/en
Priority to EP95940401A priority patent/EP0742794A1/fr
Priority to JP8517466A priority patent/JPH09503232A/ja
Publication of WO1996017869A2 publication Critical patent/WO1996017869A2/fr
Publication of WO1996017869A3 publication Critical patent/WO1996017869A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Antagonistes d'interleukine-6 (IL-6) caractérisés en ce qu'ils sont constitués de formes solubles du récepteur α de l'IL-6 humaine (shIL-6Rα) renfermant une ou plusieurs mutations au niveau de l'interface de liaison gp130. Selon le mode préféré de réalisation, les mutations sont présentes dans une position choisie dans le groupe qui comporte Ala 228, Asn 230, His 280 et Asp 281. Ces antagonistes sont utilisables comme agents permettant la prophylaxie et le traitement des maladies dues à une activité anormale de l'IL-6. La figure 4 représente l'activité antagoniste du mutant Ala228Asp/Asn 230Asp/His280Ser/Asp281Val en comparaison avec les propriétés agonistes du shIL-6Rα de type sauvage. Cet antagoniste est utilisable dans la préparation de médicaments destinés à la prophylaxie, à la maîtrise et au traitement des maladies dues à une bioactivité anormale de l'IL-6.
PCT/IT1995/000208 1994-12-06 1995-12-05 Antagonistes d'interleukine-6 (il-6) WO1996017869A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU41866/96A AU4186696A (en) 1994-12-06 1995-12-05 Interleukin-6 (il-6) antagonists
EP95940401A EP0742794A1 (fr) 1994-12-06 1995-12-05 Antagonistes d'interleukine-6 (il-6)
JP8517466A JPH09503232A (ja) 1994-12-06 1995-12-05 ＧＰ１３０結合界面で突然変異したインターロイキン−６（ＩＬ−６）受容体αの可溶性型であるＩＬ−６アンタゴニスト

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM94A000794 1994-12-06
ITRM940794A IT1274350B (it) 1994-12-06 1994-12-06 Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130

Publications (2)

Publication Number Publication Date
WO1996017869A2 WO1996017869A2 (fr) 1996-06-13
WO1996017869A3 true WO1996017869A3 (fr) 1996-08-29

Family

ID=11402851

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT1995/000208 WO1996017869A2 (fr) 1994-12-06 1995-12-05 Antagonistes d'interleukine-6 (il-6)

Country Status (7)

Country Link
EP (1) EP0742794A1 (fr)
JP (1) JPH09503232A (fr)
CN (1) CN1139933A (fr)
AU (1) AU4186696A (fr)
CA (1) CA2177837A1 (fr)
IT (1) IT1274350B (fr)
WO (1) WO1996017869A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
CA2230949C (fr) * 1995-09-28 2009-11-17 Judith Chebath Peptides synthetiques inhibant l'activite de l'interleukine 6
US6217858B1 (en) 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
GB9621095D0 (en) * 1996-10-09 1996-11-27 Imperial College Novel system
EP0983767B1 (fr) 1997-03-21 2008-09-10 Chugai Seiyaku Kabushiki Kaisha Substances servant à la prévention ou au traitement de la sclérose en plaques contenant comme principe actif des anticorps antagonistes contre le récepteur de l' IL-6
US7227837B1 (en) 1998-04-30 2007-06-05 At&T Labs, Inc. Fault tolerant virtual tandem switch
CA2237915A1 (fr) 1998-05-19 1999-11-19 Stephen Shaughnessy Traitement de l'osteoporose
US8440196B1 (en) 1998-08-24 2013-05-14 Chugai Seiyaku Kabushiki Kaisha Treatment for pancreatitis using IL-6 receptor antagonist antibodies
JP4799516B2 (ja) * 1998-08-24 2011-10-26 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する膵炎の予防又は治療剤
ATE372126T1 (de) * 1998-11-05 2007-09-15 Omeros Corp Spüllösung und verfahren zur schmerzlinderung und entzündungshemmung
WO2001016166A2 (fr) 1999-08-27 2001-03-08 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Polypeptides comprenant des domaines de recepteur d'interleukine-6 se liant a un ligand, acides nucleiques correspondants, anticorps, compositions, et leurs procedes d'utilisation
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
AUPR769501A0 (en) * 2001-09-14 2001-10-11 Biomolecular Research Institute Limited Cytokine receptor 1
WO2004073741A1 (fr) 2003-02-24 2004-09-02 Chugai Seiyaku Kabushiki Kaisha Traitement curatif pour les traumatismes medullaires contenant un antagoniste de l'interleukine-6
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
EP1690550B1 (fr) 2003-10-17 2012-08-08 Chugai Seiyaku Kabushiki Kaisha Agent de traitement de mesotheliome
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
BRPI0617378B8 (pt) 2005-10-14 2022-09-20 Chugai Pharmaceutical Co Ltd Uso de um inibidor de il-6 para produzir uma composição farmacêutica para suprimir dano a um ilhota transplantada depois do transplante de ilhota; e aperfeiçoar a viabilidade de uma ilhota em um transplante de ilhota
BRPI0617664B8 (pt) 2005-10-21 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (fr) 2005-11-25 2007-05-31 Keio University Agent thérapeutique pour le cancer de la prostate
JP5033643B2 (ja) 2006-01-27 2012-09-26 学校法人慶應義塾 脈絡膜血管新生を伴う疾患の治療剤
JP5754875B2 (ja) 2006-04-07 2015-07-29 国立大学法人大阪大学 筋再生促進剤
AU2008208321B2 (en) 2007-01-23 2013-03-21 Chugai Seiyaku Kabushiki Kaisha Chronic rejection inhibitor
CN104906581A (zh) 2008-06-05 2015-09-16 国立研究开发法人国立癌症研究中心 神经浸润抑制剂
WO2011149046A1 (fr) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター Agent thérapeutique contre le cancer du pancréas
PL2578231T3 (pl) 2010-05-28 2023-01-16 Chugai Seiyaku Kabushiki Kaisha Środek wzmacniający przeciwnowotworową odpowiedź limfocytów t
JP6442404B2 (ja) 2013-06-11 2018-12-19 国立研究開発法人国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
EP2898896A1 (fr) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Agents pour utilisation dans le traitement de l'inflammation de la rétine
ES2967627T3 (es) 2015-02-27 2024-05-03 Chugai Pharmaceutical Co Ltd Composición para tratar enfermedades relacionadas con IL-6
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
CA3103975A1 (fr) * 2018-06-21 2019-12-26 Shattuck Labs, Inc. Proteines heterodimeres et utilisations associees
BR112021020525A2 (pt) 2019-04-17 2021-12-14 Chugai Pharmaceutical Co Ltd Agente terapêutico para câncer urológico que se caracteriza por ser administrado com inibidor de il-6 e inibidor de ccr2 em combinação
CN110133241B (zh) * 2019-05-21 2022-05-27 中国食品药品检定研究院 一种测定重组人可溶性gp130-Fc融合蛋白生物学活性的新方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0591892A (ja) * 1991-10-02 1993-04-16 Chuzo Kishimoto Ｉｌ−６レセプター誘導体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0591892A (ja) * 1991-10-02 1993-04-16 Chuzo Kishimoto Ｉｌ−６レセプター誘導体

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE STRAND TPSD *
DATABASE WPI Week 9320, Derwent World Patents Index; AN 93-161739, XP002003861 *
LIAUTARD ET AL.: "Epitope analysis of human IL-6 receptor gp80 molecule with monoclonal antibodies", EUR. CYTOKINE NETWORK, vol. 5, no. 3, May 1994 (1994-05-01) - June 1994 (1994-06-01), pages 293 - 300, XP000571448 *
SALVATI ET AL.: "Interleukin-6 (IL-6) antagonism by soluble IL-6 receptor alpha mutated in the predicted gp130-binding interface", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 20, 19 May 1995 (1995-05-19), pages 12242 - 12249, XP000566420 *
TAGA ET AL.: "Interleukin-6 receptor and a unique mechanism of its signal transduction", COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, vol. 54, 1989, pages 713 - 722, XP002003860 *
YAWATA ET AL.: "Structure-function analysis of human IL-6 receptor : dissociation of amino acid residues required for IL-6-binding and IL-6 signal transduction through gp130", EMBO J., vol. 12, no. 4, 1993, pages 1705 - 1712, XP002003859 *

Also Published As

Publication number Publication date
EP0742794A1 (fr) 1996-11-20
CA2177837A1 (fr) 1996-06-07
CN1139933A (zh) 1997-01-08
AU4186696A (en) 1996-06-26
IT1274350B (it) 1997-07-17
ITRM940794A1 (it) 1996-06-06
WO1996017869A2 (fr) 1996-06-13
ITRM940794A0 (it) 1994-12-06
JPH09503232A (ja) 1997-03-31

Similar Documents

Publication Publication Date Title
WO1996017869A3 (fr) Antagonistes d'interleukine-6 (il-6)
Maurset et al. Comparison of ketamine and pethidine in experimental and postoperative pain
Chandra et al. Gabapentin versus nortriptyline in post-herpetic neuralgia patients: a randomized, double-blind clinical trial--the GONIP Trial.
CA2305799A1 (fr) Composition de traitement de la dependance a la nicotine contenant un antagoniste du recepteur a la nicotine et medicament antidepresseur ou anxiolytique
NZ305166A (en) 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
DE69834268D1 (de) Peroral zu verabreichende arzneiform enthaltend eine kombination von einem opioid agonisten und naltrexon
SI0751129T1 (en) Substituted dihydrodibenzo(b,f)azepines, method for their preparation, their use in the treatment of some central nervous system disorders, and pharmaceutical compositions containing them
Seibel et al. Cyclosporine‐induced gingival overgrowth in beagle dogs
EP0715855A3 (fr) Recepteurs antagonistes NK-1 et recepteurs antagonistes 5HT3 pour le traitement des vomissements
HUP0101369A3 (en) Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
NZ592039A (en) Combination therapy for the treatment of ocular neovascular disorders
ATE547119T1 (de) Präventives oder therapeutisches mittel mit einem il-6-antagonisten als wirkstoff für durch sensibilisierte t-zellen vermittelte erkrankungen
WO1998008546A3 (fr) Combinaisons therapeutiques d'antagonistes de rar et d'agonistes de rxr
HUP0100786A3 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
NZ516477A (en) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
AU2928292A (en) Human il-4 mutant proteins
CA2176298A1 (fr) Traitement a l'aide de fluoroquinolone, en dose unique elevee
CA2132544A1 (fr) Antagonistes d'angiotensine ii utiles contre les troubles lies a une vitesse alteree de l'influx nerveux, particulierement dans le cas de la neuropathie diabetique
WO2000002551A3 (fr) Procedes et composes permettant de traiter la depression et d'autres troubles
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
WO2023009615A3 (fr) Procédés et compositions pour traiter ou prévenir une lésion neurologique ou des troubles neurologiques
WO2000025766A3 (fr) Traitement de l'asthme gastrique
Risner et al. Intravenous self-administration of fencamfamine and cocaine by beagle dogs under fixed-ratio and progressive-ratio schedules of reinforcement
WO1998003178A3 (fr) Compositions pharmaceutiques contenant des antagonistes de recepteur purinergique p2y
EP0799618A3 (fr) Utilisation d'antagonistes de l'adrénorécepteur alpha 1 dans la fabrication d'unmédicament pur la prévention et au traitment du cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 95191457.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 1995940401

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2177837

Country of ref document: CA

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 1996 687490

Country of ref document: US

Date of ref document: 19961016

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1995940401

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995940401

Country of ref document: EP